Insider Transactions in Q1 2025 at Travere Therapeutics, Inc. (TVTX)
Insider Transaction List (Q1 2025)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 12
2025
|
William E. Rote SENIOR VICE PRESIDENT, R&D |
SELL
Open market or private sale
|
Direct |
5,200
-5.01%
|
$119,600
$23.53 P/Share
|
|
Feb 12
2025
|
Peter Heerma CHIEF COMMERCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
2,568
-2.01%
|
$59,064
$23.53 P/Share
|
|
Feb 12
2025
|
Elizabeth E Reed SVP, GC & CORPORATE SECRETARY |
SELL
Open market or private sale
|
Direct |
8,000
-8.21%
|
$184,000
$23.53 P/Share
|
|
Feb 12
2025
|
Jula Inrig CHIEF MEDICAL OFFICER |
SELL
Open market or private sale
|
Direct |
2,568
-2.79%
|
$59,064
$23.53 P/Share
|
|
Feb 11
2025
|
Peter Heerma CHIEF COMMERCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
3,074
-2.35%
|
$76,850
$25.0 P/Share
|
|
Feb 11
2025
|
Sandra Calvin SVP, CHIEF ACCOUNTING OFFICER |
SELL
Open market or private sale
|
Direct |
54,244
-14.86%
|
$1,356,100
$25.0 P/Share
|
|
Feb 11
2025
|
Sandra Calvin SVP, CHIEF ACCOUNTING OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
45,000
+12.97%
|
$720,000
$16.77 P/Share
|
|
Feb 11
2025
|
Eric M Dube CHIEF EXECUTIVE OFFICER |
SELL
Open market or private sale
|
Direct |
11,375
-2.64%
|
$273,000
$24.04 P/Share
|
|
Feb 10
2025
|
William E. Rote SENIOR VICE PRESIDENT, R&D |
BUY
Exercise of conversion of derivative security
|
Direct |
8,000
+7.16%
|
-
|
|
Feb 10
2025
|
Peter Heerma CHIEF COMMERCIAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
8,000
+5.77%
|
-
|
|
Feb 10
2025
|
Elizabeth E Reed SVP, GC & CORPORATE SECRETARY |
BUY
Exercise of conversion of derivative security
|
Direct |
8,000
+7.58%
|
-
|
|
Feb 10
2025
|
Jula Inrig CHIEF MEDICAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
8,000
+7.99%
|
-
|
|
Feb 06
2025
|
Roy D. Baynes |
SELL
Open market or private sale
|
Direct |
10,000
-24.39%
|
$220,000
$22.0 P/Share
|
|
Feb 06
2025
|
Roy D. Baynes |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+19.61%
|
$170,000
$17.44 P/Share
|
|
Feb 04
2025
|
Jula Inrig CHIEF MEDICAL OFFICER |
SELL
Open market or private sale
|
Direct |
1,066
-1.25%
|
$21,320
$20.11 P/Share
|
|
Feb 03
2025
|
Sandra Calvin SVP, CHIEF ACCOUNTING OFFICER |
SELL
Open market or private sale
|
Direct |
3,348
-5.0%
|
$66,960
$20.12 P/Share
|
|
Feb 03
2025
|
Christopher R. Cline CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
5,192
-5.45%
|
$103,840
$20.12 P/Share
|
|
Feb 03
2025
|
Peter Heerma CHIEF COMMERCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
5,166
-4.04%
|
$103,320
$20.12 P/Share
|
|
Feb 03
2025
|
Jula Inrig CHIEF MEDICAL OFFICER |
SELL
Open market or private sale
|
Direct |
4,207
-4.7%
|
$84,140
$20.12 P/Share
|
|
Feb 03
2025
|
Eric M Dube CHIEF EXECUTIVE OFFICER |
SELL
Open market or private sale
|
Direct |
50,691
-10.53%
|
$1,013,820
$20.21 P/Share
|
|
Feb 03
2025
|
Elizabeth E Reed SVP, GC & CORPORATE SECRETARY |
SELL
Open market or private sale
|
Direct |
8,951
-9.09%
|
$170,069
$19.78 P/Share
|
|
Feb 03
2025
|
William E. Rote SENIOR VICE PRESIDENT, R&D |
SELL
Open market or private sale
|
Direct |
8,951
-8.55%
|
$170,069
$19.78 P/Share
|
|
Jan 31
2025
|
Sandra Calvin SVP, CHIEF ACCOUNTING OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
13,000
+16.25%
|
-
|
|
Jan 31
2025
|
Christopher R. Cline CHIEF FINANCIAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
21,500
+18.42%
|
-
|
|
Jan 31
2025
|
Peter Heerma CHIEF COMMERCIAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
21,500
+14.39%
|
-
|
|
Jan 31
2025
|
Jula Inrig CHIEF MEDICAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
30,000
+25.12%
|
-
|
|
Jan 31
2025
|
Eric M Dube CHIEF EXECUTIVE OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
130,000
+21.27%
|
-
|
|
Jan 31
2025
|
Elizabeth E Reed SVP, GC & CORPORATE SECRETARY |
BUY
Grant, award, or other acquisition
|
Direct |
21,500
+17.93%
|
-
|
|
Jan 31
2025
|
William E. Rote SENIOR VICE PRESIDENT, R&D |
BUY
Grant, award, or other acquisition
|
Direct |
21,500
+17.04%
|
-
|
|
Jan 23
2025
|
Roy D. Baynes |
SELL
Open market or private sale
|
Direct |
16,000
-34.04%
|
$320,000
$20.0 P/Share
|
|
Jan 23
2025
|
Roy D. Baynes |
BUY
Exercise of conversion of derivative security
|
Direct |
16,000
+25.4%
|
$272,000
$17.5 P/Share
|
|
Jan 22
2025
|
William E. Rote SENIOR VICE PRESIDENT, R&D |
SELL
Open market or private sale
|
Direct |
2,437
-2.85%
|
$46,303
$19.46 P/Share
|
|
Jan 22
2025
|
Peter Heerma CHIEF COMMERCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
1,584
-1.47%
|
$28,512
$18.94 P/Share
|
|
Jan 22
2025
|
Elizabeth E Reed SVP, GC & CORPORATE SECRETARY |
SELL
Open market or private sale
|
Direct |
2,437
-3.07%
|
$46,303
$19.46 P/Share
|
|
Jan 22
2025
|
Eric M Dube CHIEF EXECUTIVE OFFICER |
SELL
Open market or private sale
|
Direct |
10,736
-2.97%
|
$203,984
$19.46 P/Share
|
|
Jan 22
2025
|
Sandra Calvin SVP, CHIEF ACCOUNTING OFFICER |
SELL
Open market or private sale
|
Direct |
925
-1.68%
|
$16,650
$18.94 P/Share
|
|
Jan 22
2025
|
Christopher R. Cline CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
865
-1.16%
|
$15,570
$18.94 P/Share
|
|
Jan 06
2025
|
Jula Inrig CHIEF MEDICAL OFFICER |
SELL
Open market or private sale
|
Direct |
440
-0.73%
|
$7,920
$18.76 P/Share
|
|
Jan 03
2025
|
Jula Inrig CHIEF MEDICAL OFFICER |
SELL
Open market or private sale
|
Direct |
2,066
-3.34%
|
$39,254
$19.1 P/Share
|